Compare First Trust Cloud Computing ETF (SKYY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? First Trust Cloud Computing ETF trades at $158.17, while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). Which is the better fit depends on your goals.
| SKYY | VRTX | |
|---|---|---|
52-Week High | $168.91 | $557.96 |
52-Week Low | $104.16 | $376.62 |
Market Cap | — | $134.06B |
Sector | — | Health |
Enterprise Value | — | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SKYY, the First Trust Cloud Computing ETF, trades at $159.62, down 1.2% on the day. Technical indicators show a neutral to bullish bias, with moving averages bullish and oscillators neutral. Recent news highlights strong AI-driven demand for cloud infrastructure, positioning SKYY to benefit from secular trends in cloud migration and data center investments.
The outlook for SKYY is positive, driven by AI adoption and cloud spending growth, but risks include market volatility and sector competition. Analyst sentiment is supportive, with the ETF offering diversified exposure without heavy concentration in mega-cap tech stocks.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
